



Bioactivity of Transition Metal-Based Complexes

Guest Editors:

Dr. Snežana Jovanović-Stević

University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovića 69, 34000 Kragujevac, Serbia

Dr. Tanja Soldatović

Department of Natural-Mathematical Sciences, State University of Novi Pazar, 36300 Novi Pazar, Serbia

Dr. Ralph Puchta

Department of Chemistry and Pharmacy, Inorganic and organometallic chemistry, Egerlandstr. 1, 91058 Erlangen, Germany

Message from the Guest Editors

Dear Colleagues,

The application of transition metal complexes in chemotherapy is well established. Cisplatin is the first cytostatic drug based on a metal ion used in the treatment of various types of cancers. However, serious side effects and drug resistance can occur during its clinical application. Thus, huge efforts are being made in the development of metal-based complexes in order to design the compound with a superior pharmacological response, as compared to cisplatin. In recent years, numerous complexes of platinum, palladium, ruthenium, gold, rhodium, osmium, iridium, zinc, copper, and other transition metals with significant antitumor activity against various carcinogenic cells in vitro and in vivo have been synthesized. In this Special Issue, we wish to address the most recent advances in the field of transition metal-based complexes and their potential clinical use by hosting a mix of original research articles and short critical reviews.

Deadline for manuscript submissions:

closed (31 August 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Duncan H. Gregory

School of Chemistry, University of
Glasgow, University Avenue,
Glasgow G12 8QQ, UK

Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals. Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and *Inorganics* offers authors the opportunity to publish exciting new research in an open access format.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Chemistry, Inorganic & Nuclear*) / CiteScore - Q2 (*Inorganic Chemistry*)

Contact Us

Inorganics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/inorganics
inorganics@mdpi.com
[X@inorganics_MDPI](https://twitter.com/inorganics_MDPI)